mouse Nfatc2 genomic DNA, mouse Tob1 genomic DNA, mouse phosphoglycerate kinase promoter (PGK promoter), E. coli Neomycin resistance gene B6.Cg-Nfatc2<tm1Rao> Tob1<tm1Tya> B6.Cg-Nfatc2<tm1Rao> Tob1<tm1Tya> <a href='https://brc.riken.jp/mus/pcr06325'>Genotyping protocol -PCR-</a> Nfatc2遺伝子とTob1遺伝子のダブルノックアウトマウス。Nfatc2遺伝子のN末端エクソンをPGK-neoカセットで置換、Tob1遺伝子はエクソン (1エクソンからなる) をPGK-neoカセットで置換。6ヶ月齢のダブルホモマウスは、外見上特に目立った異常は認められない (Nfatc2シングルホモマウスは15-18ヶ月齢で約50%がB-cell lymphomasを発症する) 。Nfatc2ホモ/Tob1へテロ型の雌マウスは繁殖するもののミルクの分泌異常のため育仔が困難 (交配に使用する場合は里親を使用する) (ダブルホモ雌マウスは不妊) 。Nfatc2ホモ/Tob1ホモ型の雄マウスを交配に使用した場合は、産仔数が多くなり、異常分娩が多くなる。 University of Minnesota, Jamie Modiano. Nfatc2 KO（Harvard Medical School, Anjana Rao）とTob1 KO（東京大学医科学研究所 山本　雅 先生）マウスとの交配により作出。 1) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. PLOS One, 9, e100629 (2014). 2) Recipient will not backcross the BIOLOGICAL RESOURCE to establish breeding colonies for either the NFAT1 KO mice or the Tob-1KO mice. 3) Tob-1 KO mice are the property of the Okinawa Institute of Science and Technology Graduate University and are available from the RIKEN BRC. The RECIPIENT must inform the DEVELOPER (Professor Tadashi Yamamoto, Okinawa Institute of Science and Technology Graduate University) the research project using the BIOLOGICAL RESOURCE and must obtain a prior permission from him. The RECIPIENT agrees to use the BIOLOGICAL RESOUCE as collaboration with the DEVELOPER in case his ongoing research is overlapping with that of the RECIPIENT. 4) NFAT1 KO mice are the property of the LaJolla Institute for Allergy and Immunology and will not be further distributed to others. Any requests for the NFAT1 KO mice shall be referred to the LaJolla Institute for Allergy and Immunology. 5) Recipient shall acquire prior written consent from the Depositor for use of the BIOLOGICAL RESOURCE by for-profit institutions or for commercial research purposes. 6) Recipient shall acquire prior written consent from the Depositor before filing an application for a patent, or intellectual property or other rights based on the results of research using the BIOLOGICAL RESOURCE. Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> C（3〜6か月） 条件を付加する。<br>1) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. PLOS One, 9, e100629 (2014). 2) Recipient will not backcross the BIOLOGICAL RESOURCE to establish breeding colonies for either the NFAT1 KO mice or the Tob-1KO mice. 3) Tob-1 KO mice are the property of the Okinawa Institute of Science and Technology Graduate University and are available from the RIKEN BRC. The RECIPIENT must inform the DEVELOPER (Professor Tadashi Yamamoto, Okinawa Institute of Science and Technology Graduate University) the research project using the BIOLOGICAL RESOURCE and must obtain a prior permission from him. The RECIPIENT agrees to use the BIOLOGICAL RESOUCE as collaboration with the DEVELOPER in case his ongoing research is overlapping with that of the RECIPIENT. 4) NFAT1 KO mice are the property of the LaJolla Institute for Allergy and Immunology and will not be further distributed to others. Any requests for the NFAT1 KO mice shall be referred to the LaJolla Institute for Allergy and Immunology. 5) Recipient shall acquire prior written consent from the Depositor for use of the BIOLOGICAL RESOURCE by for-profit institutions or for commercial research purposes. 6) Recipient shall acquire prior written consent from the Depositor before filing an application for a patent, or intellectual property or other rights based on the results of research using the BIOLOGICAL RESOURCE. Nfatc2: Homozygote x Homozygote; Tob1: Wild-type (female) x Heterozygote (male) [or Crossing to C57BL/6J(Crlj)] Nfatc2: Homozygote x Homozygote; Tob1: Wild-type (female) x Heterozygote (male) [or Crossing to C57BL/6J(Crlj)] Nfatc2 and Tob1 double knockout mice. Approximately 50% of Nfatc2 knockout mice develop B-cell lymphomas by 15-18 months of age. But, Nfatc2 and Tob1 double knockout mice do not have obvious gross phenotypes up to 6 months of age. Salivary glands showed lymphoid infiltration into the parenchyma, but no more severe than that observed in single Nfatc2 knockout mice, suggesting Tob1 neither accelerates nor delays lymphoid hyper-reactivity observed under conditions of Nfatc2 deficiency. Nfatc2 homozygous and Tob1 heterozygous dams generally fail to produce milk (so pups must be fostered). Histologically, adult female Nfatc2 homozygous/Tob1 heterozygous mice show comparable mammary development as wild type B6 mice, suggesting the inability to nurse pups is not due to anatomic defects in mammary development. Matings using Tob1 homozygous males created larger pups and more dystocias in the females. NFAT-c2/Tob-1 double KO, DKO, B6-Nfatc2/Tob1 KO NFAT-c2/Tob-1 double KO, DKO, B6-Nfatc2/Tob1 KO Developed by Jamie Modiano, University of Minnesota. The double mutant mice were generated by crossing with Nfatc2 KO (Anjana Rao, Harvard Medical School) and Tob1 KO(Tadashi Yamamoto, The Institute of Medical Science, Tokyo University). C (3-6 months) true RBRC06325 Jaime F. Modiano Jaime F. Modiano